Conventionally, treatment of DM (types 1 and 2) involves the use of antidiabetic agents, which are grouped as noninsulin (including the biguanides (e.g., metformin), sulfonylureas (e.g., glyburide), SGLT-2 inhibitors (e.g., dapagliflozin), bile acid sequestrants (e.g., colesevelam), amylin mimetic (e.g., pramlintide), dopamine-2 agonist (e.g., bromocriptine), DPP-4 inhibitors (e.g., sitagliptin), GLP-1RAs (e.g., exenatide), thiazolidinedione (e.g., rosiglitazone), and α-glucosidase inhibitors (e.g., Acarbose and voglibose)) and insulin (e.g., human insulin and analogs) therapies [6]. This evidence concerns the gene INS and diabetes mellitus.